| Ningbo Kilo Biotechnology Co., Ltd. | China | |||
|---|---|---|---|---|
![]() | www.kilobio.com | |||
![]() | +8613989352104 | |||
![]() | terry.zhang@kilobio.com | |||
![]() | QQ Chat | |||
![]() | WeChat: Wenzhou Medical University | |||
| Chemical distributor since 2023 | ||||
| chemBlink Standard supplier since 2023 | ||||
| Classification | Biochemical >> Peptide |
|---|---|
| Name | PNC-27 |
| Synonyms | (4S)-5-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[[(2S)-5-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-4-methyl-2-[[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoic acid |
| Molecular Structure | ![]() |
| Molecular Formula | C188H293N53O44S |
| Molecular Weight | 4031.73 |
| Protein Sequence | PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG |
| CAS Registry Number | 1159861-00-3 |
| SMILES | C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]9CCCN9C(=O)[C@@H]1CCCN1)O |
|
PNC-27 was designed around a fragment of p53, a protein best known for its involvement in responses to cellular stress. The fragment corresponds to a region involved in recognition by HDM2, the human counterpart of MDM2. Researchers joined it to a membrane-active segment. The resulting peptide is a designed construct rather than a small dose of intact p53; it cannot reproduce all the functions of that large protein. A 2010 study examined the conformation of PNC-27 and its interaction with HDM2 associated with cancer cell membranes. The researchers reported membrane disruption and cell death in the experimental systems. Their account was notable because it concerned a protein at the cell surface, rather than simply assuming that the peptide entered the nucleus and restored the normal transcriptional activities of p53. Location is part of the mechanistic hypothesis. Membrane permeabilization and cancer treatment are different endpoints. Cultured cells can reveal whether a peptide disrupts a membrane under controlled conditions. They cannot establish how much intact peptide would reach a tumor in a person, how rapidly it would be cleared, or how it would interact with unrelated tissues. Nor does the observation that some cells responded differently establish universal tumor selectivity. A valid comparison depends on the cells and conditions actually studied. One reason to study a peptide's conformation is that the same chain of amino acids can expose different surfaces as it bends. A model of the binding region suggests which surface could be recognized by HDM2. A separate experiment must test whether binding occurs at the membrane and whether it is necessary for the observed effect. This distinction between structural compatibility and causal evidence is a useful feature of the PNC-27 work. The research is useful as an example of what happens when two peptide segments are combined to probe a particular molecular location. A mechanism supported in a laboratory model can motivate further testing; it is not clinical evidence of safety or benefit. PNC-27 should be described as an experimental peptide, not as a demonstrated cancer therapy. References: 1. PNC-27 conformation and interaction with membrane HDM2. PNAS (2010). https://doi.org/10.1073/pnas.0909364107 2. PubChem. PNC-27 identity record, CID 16201774. https://pubchem.ncbi.nlm.nih.gov/compound/16201774 |
| Market Analysis Reports |